Moleculin
MBRX · Nasdaq · United States
Share price · MBRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Oct 2026+2235.8%
- 21 Sep 2026-32.7%
- 31 Jul 2026-60.8%
- 30 Jul 2026-25.0%
Nothing announced by MBRX that day or the session before.
- 29 Jul 2026-37.9%
Nothing announced by MBRX that day or the session before.
- 30 Jun 2026-21.8%
- 23 Jun 2026-11.9%
Nothing announced by MBRX that day or the session before.
- 27 May 2026+11.4%
- Day beforeMoleculin: Regulation FD disclosure
- 19 May 2026+12.4%
Nothing announced by MBRX that day or the session before.
- 19 Feb 2026-44.3%
- Day beforeMoleculin: Regulation FD disclosure
Share of unusual movement by asset
For each asset, the share of MBRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Topoisomerase II (TOP2)Small molecule | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $4.5M | $7.3M | $6.5M-$9.0M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $5.5M | $7.3M | $7.6M-$6.7M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $5.4M | $10M | $13M-$6.1M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $3.7M | $6.7M | $25M-$7.2M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $3.6M | $7.6M | $7.6M-$5.6M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $3.4M | $7.7M | $6.4M-$4.6M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $4.9M | $9.4M | $11M-$6.1M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $4.1M | $11M | $4.3M-$6.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $4.3M | $17M | $5.0M-$6.7M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $3.3M | $25M | $5.6M-$7.5M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $3.9M | $32M | $6.0M-$5.1M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $5.7M | $37M | $7.9M-$6.0M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $6.0M | $50M | $8.6M-$7.6M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $4.2M | $58M | $6.8M-$8.0M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $4.6M | $66M | $6.9M-$4.8M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $4.1M | $75M | $4.4M-$4.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $16M | $8.9M | $8.4M-$23M operating cash flow | report ↗ |
For FY2025, Moleculin reported revenue of $0M (prior year $0M), R&D spend of $15.89M (down 10.4% YoY), and cash and equivalents of $8.88M. The company reported a net loss of $33.56M and a quarterly net burn of $33.56M.
Operationally, the company is advancing its pivotal Phase 2B/3 MIRACLE trial of Annamycin (AnnAraC) in relapsed/refractory AML, with a blinded preliminary readout released and interim unblinding of the first 45 efficacy-evaluable subjects expected in mid-2026, followed by an additional unblinding in the second half of 2026. The MB-106 AML clinical study report was in process with publication expected in late March 2026. Other disclosed developments include a planned Phase 1B/2 Annamycin monotherapy trial in third-line pancreatic cancer expected to begin in 2026, planned MB-109 and MB-110 trials targeting 2027 starts, an enrolling adult glioblastoma trial of WP1066 with a pediatric trial planned, and establishment of a recommended Phase 2 dose for WP1122.
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($0), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | George Robert E. · director | Award / grant (derivative) | 4,000 | — | — | Form 4 |
| 2026-11-17 | CANNON MICHAEL D · director | Award / grant (derivative) | 4,000 | — | — | Form 4 |
| 2026-11-17 | Climaco John M · director | Award / grant (derivative) | 4,000 | — | — | Form 4 |
| 2026-11-17 | Cermak Elizabeth · director | Award / grant (derivative) | 4,000 | — | — | Form 4 |
| 2026-11-16 | KLEMP WALTER V · director, CEO and President | Option exercise | 577 | — | — | Form 4 |
| 2026-11-16 | Foster Jonathan P. · Chief Financial Officer | Option exercise | 362 | — | — | Form 4 |
| 2026-11-16 | KLEMP WALTER V · director, CEO and President | Tax withholding | 141 | $7.41 | $1K | Form 4 |
| 2026-11-16 | Foster Jonathan P. · Chief Financial Officer | Tax withholding | 89 | $7.14 | $635 | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 20 reporting institutions held 0.2M shares ($317K, 14.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SABBY MANAGEMENT, LLC | 75,021 | $172K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 32,329 | $74K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 13,869 | $32K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 6,072 | $14K |
| 5 | Rockefeller Capital Management L.P. | 4,421 | $10K |
| 6 | UBS Group AG | 3,409 | $8K |
| 7 | Tower Research Capital LLC (TRC) | 1,835 | $4K |
| 8 | BlackRock, Inc. | 491 | $1K |
| 9 | EFG International AG | 434 | $994 |
| 10 | Pinnacle Wealth Planning Services, Inc. | 281 | $643 |
| 11 | NFSG Corp | 114 | $261 |
| 12 | SBI Securities Co., Ltd. | 43 | $98 |
| 13 | MORGAN STANLEY | 36 | $83 |
| 14 | Vanguard Global Advisers, LLC | 24 | $55 |
| 15 | HRT FINANCIAL LP | 13,739 | $31 |